{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:20:05Z","timestamp":1788236405625,"version":"build-2803163510"},"reference-count":60,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma is one of the most aggressive tumours, with an estimated 5-year overall survival rate of 5% and median survival of 5\u201311 months. Approximately one third of patients die of complications due to local disease progression, especially among patients with borderline resectable or locally advanced disease; hence achieving local control is significant for improved survival outcomes. Stereotactic body radiotherapy (SBRT) allows safe and effective delivery of ablative doses of radiation and is associated with improved locoregional tumour control and progression free survival. Our article describes the rationale and the safe and effective delivery of Linac-based SBRT treatment for pancreatic cancer.<\/jats:p>","DOI":"10.3390\/curroncol33090519","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:19:26Z","timestamp":1788232766000},"page":"519","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Practical Considerations in the Radiotherapy Treatment Planning for SBRT Pancreas Program"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3514-2183","authenticated-orcid":false,"given":"Kurian","family":"Joseph","sequence":"first","affiliation":[{"name":"Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada"},{"name":"Division of Radiation Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-8579","authenticated-orcid":false,"given":"Ben","family":"Burke","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada"},{"name":"Division of Medical Physics, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Heikal","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada"},{"name":"Division of Medical Physics, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7977-4847","authenticated-orcid":false,"given":"Eugene","family":"Yip","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada"},{"name":"Division of Medical Physics, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannah","family":"Murland","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence","family":"Wong","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beena","family":"Kunheri","sequence":"additional","affiliation":[{"name":"Kent Oncology Center, Maidstone and Tunbridge Wells NHS Trust, Maidstone, ME16 9QU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref_1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.7314\/APJCP.2015.16.14.5619","article-title":"Pancreatic Cancer: Pathogenesis and Diagnosis","volume":"16","author":"Goral","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1503\/cmaj.121368","article-title":"Diagnosis and management of pancreatic cancer","volume":"185","author":"Kanji","year":"2013","journal-title":"CMAJ"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Gillen, S., Schuster, T., Meyer zum B\u00fcschenfelde, C., Friess, H., and Kleeff, J. (2010). Preoperative\/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med., 7.","DOI":"10.1371\/journal.pmed.1000267"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/fon.15.335","article-title":"The Role of Neoadjuvant Therapy in Pancreatic Cancer: A Review","volume":"12","author":"Russo","year":"2016","journal-title":"Futur. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.53","article-title":"Pancreatic cancer: From state-of-the-art treatments to promising novel therapies","volume":"12","author":"Hidalgo","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: A randomized controlled trial","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.prro.2019.11.005","article-title":"Pancreas SBRT: Who, What, When, Where, and How\u2026","volume":"10","author":"Bernard","year":"2020","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2007.15.8469","article-title":"Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins Hospital","volume":"26","author":"Herman","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1245\/s10434-009-0743-7","article-title":"Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital\u2014Mayo Clinic Collaborative Study","volume":"17","author":"Hsu","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"LAP07 Trial Group. Effect of Chemoradiotherapy vs. Chemotherapy on Survival in Patients with Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine with or Without Erlotinib: The LAP07 Randomized Clinical Trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1245\/s10434-011-1630-6","article-title":"Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup\/RTOG 9704 Phase III Trial","volume":"18","author":"Regine","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological Benefits of Neoadjuvant Chemoradiation with Gemcitabine Versus Upfront Surgery in Patients with Borderline Resectable Pancreatic Cancer","volume":"268","author":"Jang","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/COC.0b013e3181e9c103","article-title":"A Phase II Study of gemcitabine in combination with radiation therapy with localized, unresectable, pancreatic cancer: A Hoosier Oncology Group Study","volume":"34","author":"Cardenes","year":"2011","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2007.13.9014","article-title":"Full-Dose Gemcitabine with Concurrent Radiation Therapy in Patients with Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial","volume":"26","author":"Small","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_18","first-page":"2246","article-title":"Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma","volume":"7","author":"Wolff","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/13651820510028963a","article-title":"The role of chemoradiation therapy in locally advanced pancreatic cancer","volume":"7","author":"White","year":"2005","journal-title":"HPB"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ccr.2005.07.014","article-title":"Engaging the vascular component of the tumor response","volume":"8","author":"Fuks","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of Ablative Radiation Therapy with Survival Among Patients with Inoperable Pancreatic Cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijrobp.2016.10.030","article-title":"Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials","volume":"97","author":"Petrelli","year":"2017","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiother. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-019-1309-x","article-title":"Ablative radiation therapy for locally advanced pancreatic cancer: Techniques and results","volume":"14","author":"Reyngold","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lin, T., Reddy, A., Hill, C., Sehgal, S., He, J., Zheng, L., Herman, J., Meyer, J., and Narang, A. (2023). The Timing of Surgery Following Stereotactic Body Radiation Therapy Impacts Local Control for Borderline Resectable or Locally Advanced Pancreatic Cancer. Cancers, 15.","DOI":"10.3390\/cancers15041252"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2014","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1748-717X-8-148","article-title":"SBRT in unresectable advanced pancreatic cancer: Preliminary results of a mono-institutional experience","volume":"8","author":"Tozzi","year":"2013","journal-title":"Radiat. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.clon.2020.06.019","article-title":"Hypofractionated Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma","volume":"33","author":"Simoni","year":"2021","journal-title":"Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.prro.2022.02.009","article-title":"Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial","volume":"12","author":"Hill","year":"2022","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109541","DOI":"10.1016\/j.radonc.2023.109541","article-title":"Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX\u2014The LAPC-2 trial","volume":"183","author":"Land","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Bordeau, K., Michalet, M., Keskes, A., Valdenaire, S., Debuire, P., Cantaloube, M., Cabaill\u00e9, M., Portales, F., Draghici, R., and Ychou, M. (2022). Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study. Cancers, 15.","DOI":"10.3390\/cancers15010007"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Jung, J., Yoon, S.M., Park, J.-H., Seo, D.-W., Lee, S.S., Kim, M.-H., Lee, S.K., Park, D.H., Song, T.J., and Ryoo, B.-Y. (2019). Stereotactic body radiation therapy for locally advanced pancreatic cancer. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214970"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-019-03066-z","article-title":"Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer","volume":"146","author":"Shen","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jmrs.313","article-title":"Application of stereotactic body radiotherapy in advanced pancreatic cancers in Australia","volume":"66","author":"Kim","year":"2018","journal-title":"J. Med. Radiat. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1533034616650778","article-title":"Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study","volume":"16","author":"Comito","year":"2016","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.21037\/jgo-20-187","article-title":"A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses","volume":"11","author":"Liauw","year":"2020","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","article-title":"A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome","volume":"155","author":"Teriaca","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijrobp.2023.03.036","article-title":"Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer","volume":"117","author":"Reyngold","year":"2023","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/SLA.0000000000006021","article-title":"Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients with Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study","volume":"279","author":"Seelen","year":"2024","journal-title":"Ann. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.gie.2018.10.047","article-title":"EUS-guided fiducial placement for GI malignancies: A systematic review and meta-analysis","volume":"89","author":"Coronel","year":"2019","journal-title":"Gastrointest. Endosc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.vgie.2019.05.007","article-title":"EUS-guided placement of fiducial markers for the treatment of pancreatic cancer","volume":"4","author":"Coronel","year":"2019","journal-title":"VideoGIE"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.3390\/curroncol31100446","article-title":"Sharing Mono-Institutional Experience of Treating Pancreatic Cancer with Stereotactic Body Radiation Therapy (SBRT)","volume":"31","author":"Waheed","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1102\/1470-7330.2004.0054","article-title":"Defining the tumour and target volumes for radiotherapy","volume":"4","author":"Burnet","year":"2004","journal-title":"Cancer Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: The report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med. Phys."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ijrobp.2010.08.003","article-title":"Interfraction Liver Shape Variability and Impact on GTV Position During Liver Stereotactic Radiotherapy Using Abdominal Compression","volume":"80","author":"Eccles","year":"2011","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/1533034615572341","article-title":"4DCT Simulation with Synchronized Contrast Injection in Liver SBRT Patients","volume":"15","author":"Helou","year":"2015","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.prro.2013.06.004","article-title":"Upper abdominal normal organ contouring guidelines and atlas: A Radiation Therapy Oncology Group consensus","volume":"4","author":"Jabbour","year":"2014","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1102\/1470-7330.2007.0013","article-title":"What\u2019s new in target volume definition for radiologists in ICRU Report 71? How can the ICRU volume definitions be integrated in clinical practice?","volume":"7","author":"Berthelsen","year":"2007","journal-title":"Cancer Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/j.prro.2019.07.018","article-title":"Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT)","volume":"10","author":"Oar","year":"2020","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Chuong, M.D., Jethwa, K.R., Ludmir, E., Narang, A., Reyngold, M., Anne, P.R., Bassetti, M., Brunner, T., Du, K.L., and Frakes, J. (2026). Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Pract. Radiat. Oncol., 1\u201349.","DOI":"10.1016\/j.prro.2026.07.002"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"101043","DOI":"10.1016\/j.phro.2026.101043","article-title":"Assessment of planning organ at risk volume margins in non-adaptive pancreatic stereotactic body radiotherapy","volume":"40","author":"Robinson","year":"2026","journal-title":"Phys. Imaging Radiat. Oncol."},{"key":"ref_55","first-page":"100797","article-title":"Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: A global consensus protocol","volume":"47","author":"Grimbergen","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1245\/s10434-024-15670-6","article-title":"Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501)","volume":"31","author":"Snyder","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"101164","DOI":"10.1016\/j.adro.2022.101164","article-title":"Dose Escalation for Pancreas SBRT: Potential and Limitations of using Daily Online Adaptive Radiation Therapy and an Iterative Isotoxicity Automated Planning Approach","volume":"8","author":"Rhee","year":"2023","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.semradonc.2025.08.002","article-title":"The Role of MR Guided Radiation Therapy in Pancreatic Cancer Treatment","volume":"35","author":"Jiang","year":"2025","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/acm2.12575","article-title":"A new frontier of image guidance: Organs at risk avoidance with MRI-guided respiratory-gated intensity modulated radiotherapy: Technical note and report of a case","volume":"20","author":"Massaccesi","year":"2019","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/519\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:01:10Z","timestamp":1788235270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090519"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090519","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}